Linagliptin
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
Linagliptin: From Type 2 Diabetes Mellitus to Opsismodysplasia
One-Sentence Summary
Linagliptin is a DPP-4 inhibitor used to regulate blood glucose in type 2 diabetes mellitus (as referenced in the drug’s own evidence base). The TxGNN model’s top-ranked prediction is Opsismodysplasia, a rare skeletal dysplasia, but this candidate is currently supported by 0 clinical trials and 0 publications — the score reflects knowledge-graph embedding similarity only, with no identified biological mechanism connecting the two.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Type 2 Diabetes Mellitus (DPP-4 inhibitor; not present in a structured license record — see note below) |
| Predicted New Indication | Opsismodysplasia |
| TxGNN Prediction Score | 94.90% |
| Evidence Level | L5 (model prediction only) |
| EU Market Status | ✗ Not Marketed |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |
Note: No taiwan_regulatory.licenses records exist for this drug, so the original indication above is inferred from the mechanistic descriptions embedded in the evidence pack’s rationale and literature fields, not from a formal license text.
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data for Linagliptin is not available (flagged as a High-severity data gap). Based on the information present in the evidence pack, Linagliptin acts through DPP-4 inhibition on the incretin/GLP-1 pathway to regulate blood glucose in type 2 diabetes.
The evidence pack’s own rationale for this candidate is explicit that no known biological connection exists between this mechanism and opsismodysplasia. Opsismodysplasia is a skeletal developmental disorder caused by INPPL1 gene mutations — a structural/genetic bone condition unrelated to glucose or incretin regulation. The high TxGNN score (94.90%, rank 37,382 of the full prediction set) reflects similarity in the model’s learned embedding space rather than a pharmacologically plausible mechanism.
Given this, the prediction should be treated as a hypothesis-generating signal only, not as evidence of therapeutic potential.
Clinical Trial Evidence
Currently no related clinical trials registered
Literature Evidence
Currently no related literature available
Safety Considerations
Please refer to the SmPC for safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: The top-ranked candidate (opsismodysplasia) has no clinical trial or literature support, and the evidence pack’s own mechanistic analysis finds no biological plausibility linking DPP-4 inhibition to this rare skeletal disorder. This is an L5, model-only signal.
To proceed, the following is needed:
- TFDA/EMA-equivalent label warnings and contraindications (currently a Blocking data gap — required before any S1 safety screening)
- Confirmed mechanism of action (MOA) data from DrugBank or another authoritative source (currently a High-severity data gap)
- A biologically grounded hypothesis connecting Linagliptin’s pharmacology to opsismodysplasia (or reconsideration of lower-ranked candidates, e.g. rank 8, pancreatic agenesis, which at least returned related literature, though still lacking direct mechanistic support)
- DDI data (current query returned “not_found”) before any combination-therapy consideration
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.